Key facts
- This page summarizes Jack Anders's Form 4 filing for Revolution Medicines, Inc. (RVMD).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 22 Jun 2021, 17:16.
Jack Anders - 17 Jun 2021 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)
- Reporting relationship
- SVP, Finance and Principal Accounting Officer
- Issuer ticker
- RVMD
- Reported as of
- 17 Jun 2021
- Net transaction value
- -$5,460
- SEC form
- 4
- Accepted by SEC
- 22 Jun 2021, 17:16:50 UTC
- Next SEC filing
- 21 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jack Anders
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jack Anders filed Form 4 for Revolution Medicines, Inc. (RVMD) on 22 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$5,460.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RVMD
transaction
Common Stock
Sale
- Transaction value
- $5,460
- Shares
- -160
- Change %
- -1.9%
- Price
- $34.12
- Shares after
- 8,358
- Date
- 17 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
Footnote F2
This transaction was executed in multiple trades in prices ranging from $33.66 to $34.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F3
Includes 614 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2021.
Footnote F4
Includes 6,938 RSUs.
SEC remarks
SVP, Finance and Principal Accounting Officer